Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Not only was there a "risk-off" mentality in the market today, but there were other fears surrounding biotech stocks in particular after a key FDA regulator resigned over the weekend. The FDA's chief ...